UCSD Cancer Center Training Program in Drug Development

描述(由申请者提供)：本次续签申请寻求资金，以继续在加州大学圣地亚哥分校摩尔综合癌症中心非常成功的癌症治疗培训(CT2)计划。CT2计划的使命是培训博士和内科科学家，他们将成为癌症治疗和诊断领域的下一代领导者，掌握成功将基于实验室的发现转化为安全有效的治疗药物和诊断方式所需的每一个主要步骤。CT2培训旨在让受训人员在癌症发展治疗和诊断领域发挥关键领导作用。CT2项目的22名教员都是癌症中心的成员，总部设在医学院、斯克里普斯海洋研究所或普通校园的10个系。每一位教师导师都是一位有成就的研究人员和教育家，都有培养优秀博士后研究员的历史。每一家公司都有大量的同行评议的癌症或癌症相关研究资金。所有参与的教职员工都在进行翻译研究，他们之所以被选中，是因为他们对新的癌症疗法感兴趣。该计划被广泛纳入癌症中心和加州大学可持续发展分校的其他癌症相关活动中。目标是在这个为期两年的项目中招募和留住8名医学和博士科学家，为他们在开发新的抗癌药物或指导使用这些药物所需的诊断方面的职业生涯奠定基础。培训计划包括三个部分：1)完成正式的教学课程，涵盖药物开发过程中必不可少的工具；2)在教师导师的指导下进行药物或诊断开发研究项目；3)要求参加美国癌症研究协会的年度会议或同等的国家药物开发会议。受训人员还将参加癌症中心和部门研讨会、研究回合和期刊俱乐部，以扩大他们对癌症研究的理解范围，并准备正式的项目计划和实践或实际拨款申请，供执行委员会审查。制定了确保所有受训人员接受负责任的研究和科学诚信原则的适当指导的方法。在全国范围内招募受训人员，并特别努力招募和留住特殊的少数群体、妇女和弱势群体候选人。在运作的头4年中，CT2项目吸引了来自全国主要研究型大学以及生物医学、血液学/肿瘤学、外科和放射学奖学金项目加州大学圣迭戈分校的学员。这项计划非常成功，以至于癌症中心建立了一个平行的计划，由捐款资助癌症治疗方面的额外奖学金。 公共卫生相关性：这项申请寻求资金，以继续加州大学圣地亚哥分校摩尔斯癌症中心以癌症药物为重点的发展疗法培训计划。我们的愿景是，当与允许个体化治疗的生物标记物相结合时，可以通过针对对肿瘤细胞生存至关重要的分子靶点的新疗法来控制癌症。该计划的使命是为博士后和内科科学家提供关于开发新型癌症疗法的每个主要步骤的培训，以便使这些人在将基于实验室的发现转化为安全有效的治疗剂方面发挥主导作用。

DESCRIPTION (provided by applicant): This renewal application seeks funding to continue the highly successful Cancer Therapeutics Training (CT2) Program at the Moores Comprehensive Cancer Center at the University of California, San Diego. The mission of the CT2 program is to train the PhD and physician-scientists who will become the next generation of leaders in the field of cancer therapeutics and diagnostics in each of the major steps required for successful translation of laboratory-based discoveries into safe and effective therapeutic agents and diagnostic modalities. The CT2 training is designed to position trainees to play key leadership roles in the field of cancer developmental therapeutics and diagnostics. The 22 faculty of the CT2 Program are all Members of the Cancer Center and are based in 10 departments in the School of Medicine, the Scripps Oceanographic Institute or the general campus. Each faculty mentor is an accomplished investigator and educator with a history of training superb post-doctoral fellows. Each has substantial peer-reviewed cancer or cancer-related research funding. All of the participating faculty are conducting translational research and have been selected because of their interest in new cancer therapeutics. This program is extensively integrated into the other cancer related activities of the Cancer Center and of UCSD. The goal is to recruit and retain 8 MD and PhD scientists in this two-year program that will position them for careers in the development of new cancer drugs or the diagnostics needed to guide the use of these drugs. The training program has 3 components: 1) the completion of formal didactic teaching sessions that cover tools essential to the drug development process; 2) the conduct of a drug or diagnostic development research project under the direction of a faculty mentor; and, 3) required participation in the annual meeting of the American Association for Cancer Research or an equivalent national drug development meeting. Trainees are also expected to participate in Cancer Center and Departmental seminars, research rounds and journal clubs to expand the breadth of their understanding of cancer research, and prepare formal project plans and practice or real grant applications for review by the Executive Committee. Methods are in place to ensure that all trainees are properly instructed in the principles of responsible conduct of research and scientific integrity. Trainees are recruited nationwide and special efforts are made recruit and retain exceptional minority, women and disadvantaged candidates. During its first 4 years of operation the CT2 Program has drawn trainees from major research universities across the country as well as from the Gradate Biomedical Sciences, Hematology/Oncology, Surgery and Radiology fellowship programs UCSD. This Program has been so successful that the Cancer Center has established a parallel program of additional fellowships in cancer therapeutics funded by donations. PUBLIC HEALTH RELEVANCE: This application seeks funding to continue a training program in developmental therapeutics focused on cancer drugs at the Moores Cancer Center at the University of California, San Diego. Our vision is that cancer can be controlled with novel therapeutics directed at molecular targets critical for tumor cell survival when combined with biomarkers that allow individualization of treatment. The mission of the program is to provide training to post-doctoral PhD and physician-scientists in each of the major steps in the development of a novel cancer therapeutics so as to position these individuals to play leading roles in translating laboratory-based discoveries into safe and effective therapeutic agents.